Discover why Vertex stock is undervalued with the potential of VX-548 as a groundbreaking pain treatment drug in the ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The biotech stock's price-to-earnings-to-growth (PEG) ratio is a super-low 0.58, according to the London Stock Exchange Group (LSEG). Any PEG ratio below 1.0 is viewed as an attractive valuation.

The FDA should have more big news for Vertex only a few weeks later. It expects to announce an approval decision on ...

Vertex said sickle cell patients had not yet received infusions of its gene therapy Casgevy. That’s now changed, as the ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

No patients have received Casgevy, CRISPR Therapeutics and Vertex Pharmeceuticals’ recently approved sickle cell gene therapy ...

In the meantime current gene therapies remain expensive and challenging to scale up because each patient’s batch of cells has ...

Some people of West African of descent face a higher risk of renal failure. New drugs based on gene research may help right ...

Kendric Cromer, 12, is among the first patients to be treated with gene therapy just approved by the F.D.A. that many other ...

Jupiter Endovascular today announced the first two patients treated in a study of its Vertex pulmonary embolectomy system.

Ginkgo Bioworks introduces a protein large language model and API, developed with Google Cloud, to streamline drug discovery ...